[go: up one dir, main page]

AR070046A1 - FORM A CRYSTALLINE OF ACID (2R) - (3-AMINO-2-FLUORPROPIL) PHOSPHINIC - Google Patents

FORM A CRYSTALLINE OF ACID (2R) - (3-AMINO-2-FLUORPROPIL) PHOSPHINIC

Info

Publication number
AR070046A1
AR070046A1 ARP080105599A ARP080105599A AR070046A1 AR 070046 A1 AR070046 A1 AR 070046A1 AR P080105599 A ARP080105599 A AR P080105599A AR P080105599 A ARP080105599 A AR P080105599A AR 070046 A1 AR070046 A1 AR 070046A1
Authority
AR
Argentina
Prior art keywords
amino
crystalline form
crystalline
acid
fluorpropil
Prior art date
Application number
ARP080105599A
Other languages
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR070046A1 publication Critical patent/AR070046A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a una forma cristalina de ácido (2R)-(3-amino-2-fluoropropil)fosfínico. Además, la presente se dirige al uso de la forma cristalina para el tratamiento de trastornos gastrointestinales, al igual que a composiciones farmacéuticas que comprenden dicha forma cristalina, y a un proceso para la preparacion de la forma cristalina. Reivindicacion 2: El compuesto ácido (2R)-(3-amino-2-fluoropropil)fosfínico, forma C, caracterizado porque proporciona un patron de difraccion de polvo de rayos X que exhibe sustancialmente el siguiente pico con valor d: 5,8 L.This refers to a crystalline form of (2R) - (3-amino-2-fluoropropyl) phosphic acid. In addition, the present is directed to the use of the crystalline form for the treatment of gastrointestinal disorders, as well as to pharmaceutical compositions comprising said crystalline form, and to a process for the preparation of the crystalline form. Claim 2: The compound (2R) - (3-amino-2-fluoropropyl) phosphine, form C, characterized in that it provides an X-ray powder diffraction pattern that exhibits substantially the following peak with a d-value: 5.8 L .

ARP080105599A 2007-12-21 2008-12-19 FORM A CRYSTALLINE OF ACID (2R) - (3-AMINO-2-FLUORPROPIL) PHOSPHINIC AR070046A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1583307P 2007-12-21 2007-12-21

Publications (1)

Publication Number Publication Date
AR070046A1 true AR070046A1 (en) 2010-03-10

Family

ID=40801459

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105599A AR070046A1 (en) 2007-12-21 2008-12-19 FORM A CRYSTALLINE OF ACID (2R) - (3-AMINO-2-FLUORPROPIL) PHOSPHINIC

Country Status (5)

Country Link
AR (1) AR070046A1 (en)
PE (1) PE20091176A1 (en)
TW (1) TW200940560A (en)
UY (1) UY31555A1 (en)
WO (1) WO2009082348A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904508D0 (en) * 1999-12-09 1999-12-09 Astra Ab New compounds
SE0102057D0 (en) * 2001-06-08 2001-06-08 Astrazeneca Ab New Salts I
WO2009014490A1 (en) * 2007-07-25 2009-01-29 Astrazeneca Ab Combination of (3-amino-2-fluoropropyl)phosphinic acid and omeprazole for treating tlesr, gerd, and nerd

Also Published As

Publication number Publication date
WO2009082348A1 (en) 2009-07-02
UY31555A1 (en) 2009-08-03
PE20091176A1 (en) 2009-09-03
TW200940560A (en) 2009-10-01

Similar Documents

Publication Publication Date Title
EA201170053A1 (en) METHOD OF OBTAINING AND DRYING OF SOLID RADUGLINE IN THE FORM OF BASIS
CO6551760A2 (en) RIFAXIMINE POLISH, PROCESS TO PREPARE IT AND CONTROLLED RELEASE COMPOSITIONS CONTAINING SUCH USEFUL RIFAEIMINE TO OBTAIN A LONG-TERM EFFECT
MX2013012289A (en) Triazolopyridines.
WO2009016410A3 (en) Chemical compounds 831
CN102036649A8 (en) Arginine salt and its purposes for treating mouth disease
BRPI0603059A (en) crystalline form v of agomelatine, a process for its preparation and pharmaceutical compositions containing
MY151295A (en) Pyrimidyl indoline compound
DOP2011000196A (en) PURINE COMPOUNDS
AR088755A1 (en) SOLID FORMS OF A TRANSTIRETIN DISOCIATION INHIBITOR
UA105229C2 (en) Pharmaceutical formulation
UY31885A (en) DERIVED FROM THE 1, 3, 5-TRIAZINA-2, 4-DIAMINAS-6-SUBSTITUTED-N-SUBSTITUTED AND PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, COMPOSITIONS AND APPLICATIONS.
BR112015023705A2 (en) compound of formula (ia) or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, pharmaceutical composition, use of a compound, compound and method for synthesis of the compound of formula (ia)
AR082804A1 (en) CRYSTAL FORMS OF AN XA FACTOR INHIBITOR
CU20120171A7 (en) SUBSTITUTED TRIAZOLOPIRIDINS
AR079957A1 (en) DERIVATIVES OF FATTY ACIDS OF SALICILATOS PHARMACEUTICAL COMPOSITIONS AND USE OF THE SAME
NZ714558A (en) Formulation comprising a hypolipidemic agent
WO2011023367A3 (en) Bisphosphonate-prodrugs
NZ714273A (en) Pharmaceutical composition comprising the combination of a biocompatible nanoparticle and a compound of interest, preparation and uses thereof
PE20130212A1 (en) ST-246 POLYMORPHIC FORMS AND PREPARATION METHODS
NZ600263A (en) 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof
GEP20125433B (en) α CRYSTALLINE FORM OF THE ARGININE SALT OF PERINDOPRIL, PROCESS FOR PREPARING IT, AND PHARMACEUTICAL COMPOSITIONS COMPRISING IT
IN2012DN04868A (en)
SI2081904T1 (en) Aripiprazole hemifumarate and process for its preparation
MX2013002620A (en) Novel n-hydroxy-benzamides for the treatment of cancer.
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease

Legal Events

Date Code Title Description
FB Suspension of granting procedure